The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Immunodiagnostic Systems Hldgs PLC

24 May 2021 13:39

RNS Number : 6177Z
Immunodiagnostic Systems Hldgs PLC
24 May 2021
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Immunodiagnostic Systems Holdings plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Immunodiagnostic Systems Holdings plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

21 May 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

NIL

0

NIL

0

(2) Cash-settled derivatives:

 

NIL

0

NIL

0

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

NIL

0

NIL

0

 

TOTAL:

NIL

0

NIL

0

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Interests of directors of Immunodiagnostic Systems Holdings plc in Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each

 

Name

Number of ordinary shares of 2 pence each

Percentage of total issued share capital (%) (excluding treasury shares and any shares held under option)

Klaus Peter Kaspar

18,100

0.06

Paul James Martin

22,350

0.08

Jaap Stuut

7,500

0.03

Peter John Williamson

45,000

0.16

Burkhard Wittek*

8,259,759

28.70

 

*Dr Wittek's shares are held by Forum Venture Capital GmbH, Forum European Smallcaps GmbH, Forum Family Office Venture Fund and his spouse and children

 

b) Details of awards granted to the directors of Immunodiagnostic Systems Holdings plc over Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each

Name

Number of ordinary shares of 2 pence each

Percentage of total issued share capital (%) (excluding any shares held under option)

Grant date

Vesting date

Exercise price (p)

Expiry date

Jaap Stuut

7,500

0.03

29/03/18

29/03/21

220

29/03/28

Jaap Stuut

7,500

0.03

28/03/19

06/12/21

190

28/03/29

Jaap Stuut

7,500

0.03

31/03/20

20/02/23

210

31/03/30

Jaap Stuut

7,500

0.03

17/05/21

29/03/24

195

17/05/31

Paul Martin

30,000

0.10

28/03/17

23/06/19

132

28/03/27

Paul Martin

9,000

0.03

28/03/17

28/03/20

277.5

28/03/27

Paul Martin

6,300

0.02

29/03/18

20/06/20

290

29/03/28

Paul Martin

2,283

0.01

29/03/18

29/03/21

220

29/03/28

Paul Martin

3,717

0.01

29/03/18

29/03/21

220

29/03/28

Paul Martin

6,750

0.02

28/03/19

06/12/21

184

28/03/29

Paul Martin

30,000

0.10

25/06/19

23/06/22

180

25/06/29

Paul Martin

9,000

0.03

31/03/20

21/02/23

220

31/03/30

Paul Martin

9,000

0.03

31/03/20

23/03/23

170

31/03/30

Paul Martin

6,300

0.02

17/05/21

20/06/23

275

17/05/31

Paul Martin

6,000

0.02

17/05/21

29/03/24

195

17/05/31

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

24 May 2021

Contact name:

Paul Martin

Telephone number:

+44 ( 0) 191 519 6111

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEEAASLADXFEFA
Date   Source Headline
14th Dec 20127:00 amRNSDirectorate Change
12th Dec 20124:00 pmRNSHolding(s) in Company
12th Dec 20127:00 amRNSHolding(s) in Company
10th Dec 20126:08 pmRNSHolding(s) in Company
30th Nov 20126:15 pmRNSDirector/PDMR Shareholding
26th Nov 20127:00 amRNSHalf Yearly Report
24th Oct 201210:59 amRNSNotice of Results
19th Oct 20127:00 amRNSDirectorate Change Update
17th Oct 201211:41 amRNSSettlement on Escalon debt
1st Oct 201210:31 amRNSHolding(s) in Company
17th Sep 201212:54 pmRNSRedirectorate
14th Sep 20126:09 pmRNSAGM Result
14th Sep 20127:00 amRNSAGM Statement
15th Aug 20127:00 amRNSBoard Change
3rd Aug 20122:33 pmRNSDirector/PDMR Shareholding
30th Jul 201210:18 amRNSHolding(s) in Company
27th Jul 20129:29 amRNSHolding(s) in Company
27th Jul 20129:24 amRNSHolding(s) in Company
26th Jul 201210:30 amRNSAnnual Report and Accounts & Notice of AGM
2nd Jul 20127:00 amRNSDirectorate Change
25th Jun 20127:00 amRNSFinal Results
14th Jun 20127:00 amRNSProduct Launch
23rd Apr 201211:02 amRNSIDS Receives Prestigious Queens Award
12th Apr 20127:00 amRNSTrading Statement
4th Apr 20129:56 amRNSHolding(s) in Company
4th Apr 20127:00 amRNS1,25-Dihydroxy Vitamin D Assay Launch
14th Feb 20127:00 amRNSFDA clearance for a new specialist assay
9th Feb 20127:00 amRNSChange of Adviser
1st Feb 20123:16 pmRNSChange of Adviser
30th Jan 20128:27 amRNSDirector/PDMR Shareholding - Replacement
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
30th Jan 20127:00 amRNSDirector/PDMR Shareholding
27th Jan 20127:00 amRNSDirector/PDMR Shareholding
24th Jan 20123:18 pmRNSHolding(s) in Company
24th Jan 20122:38 pmRNSHolding(s) in Company
23rd Jan 20127:01 amRNSTrading update
12th Jan 201212:13 pmRNSHolding(s) in Company
15th Dec 201111:02 amRNSHolding(s) in Company
30th Nov 20115:23 pmRNSTotal Voting Rights
28th Nov 20117:00 amRNSInterim Results
14th Nov 20112:03 pmRNSIssue of Equity
6th Oct 20117:00 amRNSTrading Update
4th Oct 20112:45 pmRNSHolding(s) in Company
8th Sep 20115:22 pmRNSResult of AGM
8th Sep 20117:00 amRNSAGM Statement
31st Aug 20114:35 pmRNSPrice Monitoring Extension
30th Aug 20117:00 amRNSDirectorate Change
25th Jul 20117:00 amRNSDirectorate Change
29th Jun 20114:50 pmRNSExercise of Options & Total Voting Rights
27th Jun 20117:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.